The FDA has cleared Nkarta to launch a clinical trial testing its cell therapy candidate NKX019 in AAV and two other autoimmune diseases.
Nkarta gets green light from FDA to test NKX019 cell therapy in AAV – ANCA Vasculitis News
About the Author:
The FDA has cleared Nkarta to launch a clinical trial testing its cell therapy candidate NKX019 in AAV and two other autoimmune diseases.
Leave A Comment